This site is for US residents only

Overview

PANORAMA 3 (NCT02654990)

Panobinostat

A Phase II study for people with relapsed or relapsed/refractory multiple myeloma

Patients & Caregivers

1-844-327-9325

Health Care Professionals

1-844-327-9325

Find a

Trial Site

Study goal

This study is being performed to look at 3 different dosing schemes of panobinostat in combination with bortezomib and dexamethasone, and to find the optimal dosing regimen for panobinostat.

You may be eligible to participate if you

  • Have relapsed or relapsed/refractory multiple myeloma, as per International Myeloma Working Group (IMWG) 2014 definition, and are requiring treatment
  • Have measurable disease based on central protein assessment
  • Have one to three prior lines of therapy
  • Have prior immunomodulatory agent (IMiD) exposure
  • Have acceptable lab values prior to starting study treatment
  • Meet other eligibility criteria

 

LEARN MORE ABOUT YOUR ELIGIBILITY

 

Clinical Study Overview

Here is some information that may help you gain a better understanding of this study and its goals. By learning more about this study, you'll be able to make an informed decision with your doctor.

What are the possible drugs that I could receive in this study?

Study recipients will receive panobinostat, bortezomib, and dexamethasone.

In which disease is the investigational drug being studied?

Panobinostat is being studied in patients with relapsed or relapsed/refractory multiple myeloma who have been previously exposed to immunomodulatory agents such as lenalidomide or pomalidomide.

What should I know about the investigational drugs being studied?

Panobinostat is being studied in three different dosing schemes in order to find the optimal dosing regimen with bortezomib and dexamethasone.

How many patients will participate in this study?

Approximately 240 people in several countries around the world will participate in this study.

How long will I participate in this study?

Patients will be treated with the study treatment until disease progression, unless they discontinue earlier for other reasons. All patients will eventually be followed for a maximum of 3 years.

 

To learn more about this study, visit ClinicalTrials.gov.